Journal of Oncology

Research Article

Ubiquitin-Specific Peptidase 8 Modulates Cell Proliferation and Induces Cell Cycle Arrest and Apoptosis in Breast Cancer by Stabilizing Estrogen Receptor Alpha

Table 1

Clinicopathological characteristics correlate with USP8 expression.


Characteristic	Levels	Low expression of USP8	High expression of USP8	value

N		541	542

T stage, n (%)	T1	127 (11.8%)	150 (13.9%)	0.377
	T2	324 (30%)	305 (28.2%)
	T3	73 (6.8%)	66 (6.1%)
	T4	16 (1.5%)	19 (1.8%)

N stage, n (%)	N0	278 (26.1%)	236 (22.2%)	0.051
	N1	168 (15.8%)	190 (17.9%)
	N2	49 (4.6%)	67 (6.3%)
	N3	40 (3.8%)	36 (3.4%)

M stage, n (%)	M0	440 (47.7%)	462 (50.1%)	0.443
M stage, n (%)	M1	12 (1.3%)	8 (0.9%)	0.443

Pathologic stage, n (%)	Stage I	88 (8.3%)	93 (8.8%)	0.142
	Stage II	324 (30.6%)	295 (27.8%)
	Stage III	110 (10.4%)	132 (12.5%)
	Stage IV	12 (1.1%)	6 (0.6%)

Race, n (%)	Asian	25 (2.5%)	35 (3.5%)	<0.001
	Black or African American	132 (13.3%)	49 (4.9%)
	White	354 (35.6%)	399 (40.1%)

Age, n (%)	≤60	307 (28.3%)	294 (27.1%)	0.443
Age, n (%)	>60	234 (21.6%)	248 (22.9%)	0.443

Histological type, n (%)	Infiltrating ductal carcinoma	386 (39.5%)	386 (39.5%)	1.000
Histological type, n (%)	Infiltrating lobular carcinoma	103 (10.5%)	102 (10.4%)	1.000

PR status, n (%)	Negative	219 (21.2%)	123 (11.9%)	<0.001
	Indeterminate	1 (0.1%)	3 (0.3%)
	Positive	301 (29.1%)	387 (37.4%)

ER status, n (%)	Negative	176 (17%)	64 (6.2%)	<0.001
	Indeterminate	0 (0%)	2 (0.2%)
	Positive	346 (33.4%)	447 (43.2%)

HER2 status, n (%)	Negative	270 (37.1%)	288 (39.6%)	0.340
	Indeterminate	8 (1.1%)	4 (0.6%)
	Positive	82 (11.3%)	75 (10.3%)

PAM50, n (%)	Normal	23 (2.1%)	17 (1.6%)	<0.001
	LumA	237 (21.9%)	325 (30%)
	LumB	79 (7.3%)	125 (11.5%)
	Her2	51 (4.7%)	31 (2.9%)
	Basal	151 (13.9%)	44 (4.1%)

Menopause status, n (%)	Pre	106 (10.9%)	123 (12.7%)	0.499
	Peri	17 (1.7%)	23 (2.4%)
	Post	349 (35.9%)	354 (36.4%)

Anatomic neoplasm subdivisions, n (%)	Left	282 (26%)	281 (25.9%)	0.975
Anatomic neoplasm subdivisions, n (%)	Right	259 (23.9%)	261 (24.1%)	0.975

Radiation therapy, n (%)	No	221 (22.4%)	213 (21.6%)	1.000
Radiation therapy, n (%)	Yes	281 (28.5%)	272 (27.6%)	1.000

OS event, n (%)	Alive	467 (43.1%)	464 (42.8%)	0.802
OS event, n (%)	Dead	74 (6.8%)	78 (7.2%)	0.802

DSS event, n (%)	Alive	485 (45.6%)	493 (46.4%)	0.129
DSS event, n (%)	Dead	50 (4.7%)	35 (3.3%)	0.129

PFI event, n (%)	Alive	463 (42.8%)	473 (43.7%)	0.470
PFI event, n (%)	Dead	78 (7.2%)	69 (6.4%)	0.470

Age, median (IQR)		58 (48, 66)	58 (49, 68)	0.084